SwedishAmerican Life Science Summit 2009 DISCLAIMER In order

Swedish-American Life Science Summit 2009

DISCLAIMER In order to utilize the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, Biovitrum is providing the following cautionary statement. This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses of Biovitrum. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, the loss or expiration of patents, marketing exclusivity or trade marks; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of delay to new product launches; the difficulties of obtaining and maintaining governmental approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; and the risk of environmental liabilities.

Biovitrum Highlights • Swedish based specialist pharmaceuticals company – R&D, manufacturing and product sales – 400 employees, whereof 170 in R&D • International commercial presence – Europe, US, Canada, Australia & New Zealand • Eight marketed specialist pharmaceutical products • Six Phase II specialist indication protein pharmaceutical pipeline projects • Strong biotech therapeutics heritage • Solid financials – Revenues SEK 1. 14 billion (2008) – Cash position SEK 460 million (2008) • Listed on the SSE with MCAP BSEK 3. 3

The 25 Major BVT Shareholders Share holder INVESTOR AB MPM AMGEN INC MERRILL LYNCH, PIERCE, FENNER & SMITH, W 9 ORKLA ASA MSIL IPB CLIENT ACCOUNT Skagen fonder CBJER-KBCI FOR H&B CAPITAL LP LIFE EQUITY SWEDEN KB AAC CAPITAL Catella Fondförvaltning Handelsbanken fonder inkl XACT SEB Investment Management NORDEA BANK NORGE NOMINEE FJÄRDE AP-FONDEN GLADIATOR BIOVITRUM TREASURY AB (C-shares) Danske Capital Sverige AB STIFT FÖR FRÄMJANDE&UTVECKLING Swedbank Robur Fonder VPC data per 2009 -05 -29 DNB NOR Bank ASA CEO and Management Others Total Number of shares Share % 11 447 307 9 446 214 3 768 516 3 511 205 2 650 000 2 546 385 1 843 726 1 826 091 1 506 524 1 064 156 804 725 628 642 603 220 444 682 350 000 284 000 282 162 271 662 256 773 22, 9 18, 9 7, 5 7, 0 5, 3 5, 1 3, 7 3, 6 3, 0 2, 1 1, 6 1, 3 1, 2 0, 9 0, 7 0, 6 0, 5 209 200 138 900 0, 4 0, 3 4 285 347 49 995 528 8, 6 100, 0 4

Board of Directors Håkan Åström Chairman Michael Steinmetz Mats-Olof Ljungkvist Hans Wigzell Wenche Rolfsen Catarina Larsson Peter Sellei Hans Glemstedt Bo-Gunnar Rosenbrand 5

Company Organization ~175 FTEs ~ 150 FTEs ~ 25 FTEs

Senior Management Mara Berggren Hans Örström Erik Kinnman Martin Nicklasson Fredrik Berg Peter Edman Göran Arvidsson Head of HR SVP Commercial VP IR & PA, CEO General Counsel CSO CFO Operations Chief Strategic Officer SVP Legal 7

BIOVITRUM - ENTREPRENEUR WITH BIG PHARMA EXPERIENCE 8

Product Re. Facto® Disease Indication Hemophilia A ** Partner Wyeth Region* Nordic Hematol. Biovitrum’s Commercial Portfolio is Focused on Rare Diseases/Orphan Drugs Bene. FIX® Hemophilia B Wyeth Nordic Novastan® Thrombosis (HIT II) Mitsubishi Pharma Nordic Infl. Kineret® Cancer supportive care Rheumatoid arthritis Global Kepivance® Oral mucositis after chemotherapy and radiation Global Stemgen® Blood stem cell transplantation Global Aloxi® Chemotherapy-induced nausea and vomiting Helsinn Nordic Mimpara® Hypercalcemia in SHPT and PHPT Amgen Nordic * Region in which BVT has the rights to sell and promote ** Re. Facto® AF, line extention. Approved in the US as Xyntha TM, and in Europe as Re. Facto AF TM 9

Sustainable and Well-founded Growth Strategy • Expand commercial portfolio and geographical presence – Kineret®, Kepivance® and Stemgen® acquired Dec 15, 2008 • Leverage recombinant protein therapeutics expertise in a focused and flexible R&D organization • Deliver specialist indication value propositions from our R&D pipe-line – Hemophilia – Fat malabsorption – Autoimmune diseases/Inflammation 10

Growth Through Geographical & Portfolio Expansion Partnering/distribution Kineret & Kepivance • Infrastructure organization and network in Europe/North America/Australia/New Zealand – – – Marketing and sales, including proactive call centers Distributors and wholesalers Medical support Pharmacovigilance Product portfolio expansion Warehouses for the acquired inventory and cell banks 11

Strong r. DNA Biopharmaceuticals Heritage • Sole global manufacturer of Re. Facto® AF drug substance • Manufacturing processes for 6 products developed to market • More than 30 processes developed and manufactured for clinical phase – Big Pharma (Pfizer, Amgen, Wyeth) – Small/Mid sized biotech companies (e. g. Symphogen and Syntonix) • High quality CMC work enabled first clinical recombinant polyclonal antibody ever 12

Biovitrum’s Pipeline is Focused on Rare Diseases/Orphan Drugs Product Disease Indication Partner Phase Region * FIXFc Hemophilia B Biogen Idec I/II Global FVIIIFc Hemophilia A Biogen Idec Preclin Global Kiobrina™ Fat malabsorption in premature infants II Global Exinalda™ Fat malabsorption in cystic fibrosis II Global Auto immune Sym 001 Rh-immunization Symphogen II ** Global Sym 001 Platelet disorder (ITP) Symphogen II Global Cancer support. Care Kepivance® Oral mucositis after chemotherapy and radiation - pediatric (1 -16 yrs) indication I/II Global Hematol. Malabs. * Region in which BVT has the rights to sell and promote ** A dose adjusting red blood cell challenge healthy volunteer study preceding phase III 13

Why Specialist Indications/Rare Disease Focus? • Many specialist indication areas with high unmet medical needs – Segment enjoys higher growth cf. crowded primary care arena • Less R&D risk – Validated targets – No huge development programs – Biovitrum biotech therapeutics competence and specialist pharmaceuticals portfolio leverage • Rare disease drug development supported by regulators, government funds and charitable foundations – 5 -8. 000 ‘orphan’ diseases affecting 6 -8% of the population • 400 can be offered treatment – Market exclusivity (10 yrs EU, 7 yrs US) – Fee waivers, fast track/expedited review processes and protocol assistance • Access to market segments is more favorable – Marketing & sales more focused and less costly as patients and care givers can be reached at few centers

Q 2 Showed Continued Strong Revenue Growth • Revenues before licensing revenues increased by 31% to 319. 9 MSEK (243. 8) • Kineret® and Kepivance® revenues were 137 MSEK (16. 2) • Earnings 16. 8 MSEK (-98. 6) – …equivalent to earnings per share 0. 33 SEK (-2. 12) • Strong cash flow from operations 45. 1 MSEK (-75. 6)

Q 2 Showed Good Pipeline Progression • Re. Facto AF® was launched in Europe June 1 • One of two phase II Kiobrina studies, and an Exinalda Po. C study, completed patient recruitment • Good Sym 001 phase II study progression • 2 metabolic disease projects out-licensed to i. Novacia AB Events after Q 2 • Distribution agreement for Israel entered with Megapharm Ltd • American Depository Receipt program launched with The Bank of New York Mellon

Key Figures YTD June 2009 Amounts in SEK million Apr 1 - Jun 30 2009 2008 Jan 1 - Jun 30 2009 2008 Total revenues before license revenues 319. 9 243. 8 675. 1 443. 8 Profit/loss for the period Earnings/loss per share before dilution Research and development expenses Liquid funds and short-term investments 16. 8 0. 33 162. 2 341. 2 -96. 6 -2. 12 167. 7 635. 6 -6. 9 -0. 14 306. 0 341. 2 -98. 7 -2. 16 338. 6 635. 6 1) Amount including restructing expenses of SEK 120. 0 M. 1) 1)

2009 – Prioritize Delivery • Deliver the topline – Kineret®, Kepivance®, Stemgen® – Optimize the Re. Facto/Xyntha. TM business – Grow the sales in the Nordic region • Ensure future growth – Strike new partnership agreements for Kepivance® and Kineret® in new regions – Identify new product acquisitions and/or business partnerships – Progress the project pipeline – Out-license/sell the small molecule pipeline 18

Compelling Investment Opportunity Integrated specialty pharma player • Broad specialist pharmaceuticals portfolio • Integrated R&D, manufacturing and M&S organization • Industry leading protein pharmaceuticals and hemophilia expertise • Significant sales and EBITDA generated by products sales, co-promotion, royalties and manufacturing services Low risk and diverse stable cash flows Growth and expansion platform • Compelling valuation and strong financial profile with significant upside • Expanded commercial organization and portfolio enhancing attractiveness for additional product partnerships • Self-funded R&D player with valued protein pharmaceuticals development/production and partnerships • Strong balance sheet allowing strategic flexibility • Opportunity to acquire and in-license new products 19